What is the primary reason for this 8-K filing?

This 8-K filing is primarily to report on the completion of Johnson & Johnson's separation of Kenvue Inc. and to provide updated financial information and guidance to investors reflecting this significant event.

What is the Kenvue Separation?

The Kenvue Separation refers to Johnson & Johnson's strategic decision to divest its stake in Kenvue Inc., its consumer health division. This was completed via an exchange offer, resulting in Kenvue becoming an independent, publicly traded company.

How will the Kenvue Separation affect Johnson & Johnson's financials?

The separation removes Kenvue's revenue and associated costs from Johnson & Johnson's financial statements. The updated guidance provided in the filing reflects the financial impact of this divestiture, allowing investors to understand the performance of JNJ's continuing operations in pharmaceuticals and medical technology.

Where can I find the updated financial data and guidance?

The updated financial data and 2023 guidance are detailed in the press release (Exhibit 99.1) and updated financial data (Exhibit 99.2) attached to this 8-K filing.

JNJ 8-K: Earnings & Results

Summary

Johnson & Johnson (JNJ) has filed an 8-K report detailing the financial implications and updated guidance following the completion of its Kenvue Inc. separation. The company has finalized an exchange offer, effectively divesting its stake in Kenvue. This strategic move is expected to reshape JNJ's financial profile, allowing it to focus more intently on its core pharmaceutical and medical technology businesses. The press release accompanying this filing provides crucial updated financial figures and revised 2023 guidance. Investors should pay close attention to these adjustments, as they reflect the impact of the Kenvue Separation on JNJ's revenue streams, profitability, and overall financial outlook. The updated data will be essential for assessing the company's performance and future prospects as a more streamlined entity.

Key Highlights

1Johnson & Johnson has completed the separation of Kenvue Inc. through an exchange offer.
2The company has issued updated financial statements and revised 2023 guidance following the Kenvue Separation.
3The filing indicates that the separation is now finalized, marking a significant strategic shift for JNJ.
4Updated financial data reflecting the post-separation structure is available.
5Investors are provided with revised guidance for the remainder of 2023 to account for the Kenvue divestiture.

JOHNSON & JOHNSON 8-K Report, Financial Results (Aug 30, 2023)

Summary

Key Highlights

Frequently Asked Questions